Ramipril Patent Invalid Due To Obviousness: Court
An appeals court ruled on Tuesday that King Pharmaceutical's patent on its hypertension drug Altace was obvious and thus invalid, overturning a lower court's ruling that generics maker Lupin LTD infringed...To view the full article, register now.
Already a subscriber? Click here to view full article